PMN310

DRUG2 trials

Sponsors

ProMis Neurosciences, Inc

Conditions

Alzheimer Disease, Early OnsetHealthy Participants

Phase 1

A Phase 1a Study of PMN310 In Healthy Volunteers

CompletedNCT06105528

ProMis Neurosciences, IncHealthy Participants

Start: 2023-11-18End: 2024-07-31Updated: 2025-07-25

PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Active, not recruitingNCT06750432

ProMis Neurosciences, IncAlzheimer Disease, Early Onset

Start: 2024-12-13End: 2026-12-01Updated: 2026-07-13

Related Papers

PRECISE‐AD, A Phase 1b, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients with Early Alzheimer's Disease

Alzheimer s & Dementia2025-12-01